asco@alo33:161360 JSONTXT

{"project":"ASCO_abstracts","denotations":[{"id":"T1","span":{"begin":98,"end":111},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":258,"end":261},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":421,"end":434},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1071,"end":1096},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1165,"end":1189},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004989"},{"id":"A2","pred":"mondo_id","subj":"T1","obj":"0007254"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0012833"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0004989"},{"id":"A5","pred":"mondo_id","subj":"T4","obj":"0007254"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0004953"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0005023"}],"text":" Background: The proliferation marker Ki67 is an established prognostic and predictive marker in breast cancer. The association beteen Ki67 and treatment response in the neoadjuvant setting, hoever, is still unclear. We have therefore evaluated hether Ki67 can predict pathological complete response pCR in omen ith neoadjuvant chemotherapy NAC . Methods: We included prospectively collected data of omen ith primary breast cancer ho underent NAC from 20052015 at the Medical University of Vienna, Department of Gynecology. Chemotherapy consisted of 4 cycles epirubicin 90 mgm2, q3 , folloed by 4 cycles docetaxel 100 mgm2, q3 , hich as co-administered ith trastuzumab in HER2-positive tumors. Ki67, hormone receptor and HER2-status ere examined by immunohistochemistry using core needle biopsy specimens obtained prior to NAC. NAC-related effects ere evaluated in surgical specimen; pCR as defined as the absence of invasive cancer in breast and axillary nodes. Results: A total of 95 omen ith a mean age of 52.9 11.4 years at diagnosis ere identified. At biopsy, invasive ductal carcinoma as the predominant histology n = 76; 80 percent , ith accompanying ductal carcinoma in situ in 17 patients 17.9 percent . Mean Ki67 at biopsy as 47.4 22.9 percent and 29.5 25.5 percent after NAC p= 0.002 ; mean difference of Ki67 before and after NAC as -24.9 33.5 percent. After breast-conserving surgery n = 62; 65.3 percent or mastectomy n = 29; 30.5 percent , pCR as observed in 19 20 percent patients. The pCR rate as significantly higher in younger omen OR 1.04 [95 percentCI, 1.001.08]; p= 0.04 , those ith hormone-receptor-negative OR 0.77 [95 percentCI, 0.630.94]; p= 0.009 , HER2-positive disease OR 0.69 [95 percentCI, 0.550.87]; p= 0.002 and high Ki67 14 percent cut-off OR 0.95 [95 percentCI, 0.930.98]; p= 0.002 . In a multiple model including all knon potential confounders, Ki67 remained the only significant predictor for pCR after NAC p= 0.007 . No significant effect as observed ith regard to overall, disease-free and progression-free survival. Conclusions: Our study suggests that in omen treated ith anthracycline-taxane-based NAC, high pretherapeutic Ki67 is the strongest independent predictive marker for pCR.,J Clin Oncol 34, 2016 suppl; abstr e12500 ,Publication Only Breast CancerTriple Negative Breast CancerCytotoxicsLocal Therapy \n"}